Linden Advisors’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Linden Advisors’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40,008	Closed	-$404K	–	575
2022 Q4	$404K	Hold	40,008	–	–	﹤0.01%	352
2022 Q3	$396K	Sell	40,008 -638,841	-94%	-$6.31M	﹤0.01%	442
2022 Q2	$6.72M	Hold	678,849	–	–	0.06%	186
2022 Q1	$6.69M	Hold	678,849	–	–	0.04%	275
2021 Q4	$6.68M	Hold	678,849	–	–	0.04%	241
2021 Q3	$6.61M	Hold	678,849	–	–	0.04%	260
2021 Q2	$6.57M	Buy	+678,849	New	+$6.6M	0.03%	276

Linden Advisors's BIOT Position: Q1 2023 in Review

Linden Advisors sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 40,008 shares — an estimated $404K sold.

Linden Advisors first reported a position in BIOT in Q2 2021 and held it in 7 quarters. The position peaked at $6.72M in Q2 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Linden Advisors reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Linden Advisors sold 40,008 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $404K.
Linden Advisors first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Linden Advisors's Biotech Acquisition Company Class A Ordinary Shares position peaked at $6.72M in Q2 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Linden Advisors's 13F filing for Q1 2023, filed 15 May 2023.